OR WAIT 15 SECS
EL SEGUNDO, Calif. -- Computer Sciences Corporation today announced that DVC LLC, a CSC company, has entered into a phase 1 clinical trial for its recombinant plague vaccine candidate.
The trial will evaluate the safety, tolerability and immunogenicity of the
vaccine candidate in healthy volunteers between the ages of 18 and 40.
Testing is underway and will continue into 2005 at the University of Kentucky
Chandler Medical Center in Lexington, Ky. Contract research services for the
single center open-label study will be provided by the Covalent Group Inc., headquartered in Wayne, Penn.
The plague vaccine candidate is designed to provide protection against the
plague bacterium Yersinia pestis, and was originally identified and developed
by scientists working at the U.S. Army Medical Research Institute of
Infectious Diseases (USAMRIID). Their work involved the identification of
suitable protein antigens and the development of the processes used to assess
the performance of the vaccine. Further development and manufacture of the
vaccine candidate has been achieved by ID Biomedical Corporation, headquartered in Vancouver, British Columbia, under the DVC prime systems contract for the Department of Defense Joint Vaccine Acquisition Program (JVAP).
JVAP's mission is to develop, produce and stockpile FDA-licensed vaccine
products to help protect the warfighter against biological warfare agents.
JVAP consolidates the Department of Defense's efforts for the advanced
development, testing, FDA licensing, production and storage of biological
USAMRIID, located at Fort Detrick, Md., is the lead medical research
laboratory for the U.S. Biological Defense Research Program, and plays a key
role in national defense and in infectious disease research. The Institute's
mission is to conduct basic and applied research on biological threats
resulting in medical solutions (such as vaccines, drugs and diagnostics) to
protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army
Medical Research and Materiel Command.
DVC is a biopharmaceutical company dedicated to the development and
licensure of safe and efficacious biodefense vaccines and therapeutics. DVC
is part of CSC's Enforcement, Security and Intelligence organization, which
CSC created in 2002 to support programs enhancing U.S. security.
Founded in 1959, Computer Sciences Corporation is a leading global
information technology (IT) services company. CSC's mission is to provide
customers in industry and government with solutions crafted to meet their
specific challenges and enable them to profit from the advanced use of
Source: Computer Sciences Corporation